805. Amikacin Liposome Inhalation Suspension (ALIS) Add-on Therapy for Refractory Mycobacterium avium Complex (MAC) Lung Disease: Effect of In Vitro Amikacin Susceptibility on Sputum Culture Conversion

BACKGROUND: ALIS (590 mg amikacin base) is liposome-encapsulated amikacin for inhalation, which delivers amikacin directly to the lung and limits systemic exposure. In the CONVERT phase 3 trial, significantly more adults with treatment-refractory MAC lung disease receiving ALIS plus guideline-based...

Descripción completa

Detalles Bibliográficos
Autores principales: Brown-Elliott, Barbara A, Eagle, Gina, Wallace, Richard J, Van Ingen, Jakko, Pennings, Lian J, Berry, Brooke, Pandey, Sushil, Coulter, Chris, Syrmis, Melanie, Winthrop, Kevin L, Griffith, David E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253489/
http://dx.doi.org/10.1093/ofid/ofy210.812

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253489/
http://dx.doi.org/10.1093/ofid/ofy210.812

Ejemplares similares